Pinz Capital Management’s Mustang Bio MBIO Stock Holding History

Pinz Capital Management’s Portfolio MBIO Stock Details MBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-8	Closed	-$19K	–	292
2021 Q2	$19K	Sell	8 -32	-80%	-$78.4K	0.01%	373
2021 Q1	$99K	Buy	+40	New	+$119K	0.03%	241

Other funds holding MBIO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Pinz Capital Management's MBIO Position: Q3 2021 in Review

Pinz Capital Management sold out of Mustang Bio (MBIO) in Q3 2021, closing a stake of 8 shares — an estimated $19K sold.

Pinz Capital Management first reported a position in MBIO in Q1 2021 and held it in 2 quarters. The position peaked at $99K in Q1 2021. 79 funds tracked by Wall St. Rank hold MBIO as of Q3 2021.

Pinz Capital Management reported no remaining Mustang Bio position as of Q3 2021 after selling out during the quarter.
Pinz Capital Management sold 8 Mustang Bio shares in Q3 2021, an estimated $19K.
Pinz Capital Management first reported a position in Mustang Bio in Q1 2021 and held it in 2 quarters.
Pinz Capital Management's Mustang Bio position peaked at $99K in Q1 2021.
79 funds tracked by Wall St. Rank held Mustang Bio as of Q3 2021.

Based on Pinz Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.